Logo image of SXTC

CHINA SXT PHARMACEUTICALS IN (SXTC) Stock Fundamental Analysis

NASDAQ:SXTC - Nasdaq - VGG2161P1403 - Common Stock

0.4104  +0 (+0.1%)

After market: 0.41 0 (-0.1%)

Fundamental Rating

1

Overall SXTC gets a fundamental rating of 1 out of 10. We evaluated SXTC against 195 industry peers in the Pharmaceuticals industry. SXTC has a bad profitability rating. Also its financial health evaluation is rather negative. SXTC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SXTC has reported negative net income.
SXTC had a negative operating cash flow in the past year.
SXTC had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SXTC reported negative operating cash flow in multiple years.
SXTC Yearly Net Income VS EBIT VS OCF VS FCFSXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of SXTC (-13.40%) is better than 68.28% of its industry peers.
With a decent Return On Equity value of -22.24%, SXTC is doing good in the industry, outperforming 69.89% of the companies in the same industry.
Industry RankSector Rank
ROA -13.4%
ROE -22.24%
ROIC N/A
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
SXTC Yearly ROA, ROE, ROICSXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

SXTC has a Gross Margin (28.73%) which is in line with its industry peers.
In the last couple of years the Gross Margin of SXTC has declined.
The Profit Margin and Operating Margin are not available for SXTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
SXTC Yearly Profit, Operating, Gross MarginsSXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SXTC has been increased compared to 1 year ago.
The number of shares outstanding for SXTC has been increased compared to 5 years ago.
The debt/assets ratio for SXTC has been reduced compared to a year ago.
SXTC Yearly Shares OutstandingSXTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
SXTC Yearly Total Debt VS Total AssetsSXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

SXTC has an Altman-Z score of -1.40. This is a bad value and indicates that SXTC is not financially healthy and even has some risk of bankruptcy.
SXTC has a Altman-Z score (-1.40) which is in line with its industry peers.
SXTC has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
SXTC has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -1.4
ROIC/WACCN/A
WACC5.2%
SXTC Yearly LT Debt VS Equity VS FCFSXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

SXTC has a Current Ratio of 1.60. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.
SXTC has a Current ratio of 1.60. This is in the lower half of the industry: SXTC underperforms 69.35% of its industry peers.
SXTC has a Quick Ratio of 1.51. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.51, SXTC is doing worse than 64.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.51
SXTC Yearly Current Assets VS Current LiabilitesSXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

SXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.52%, which is quite impressive.
SXTC shows a decrease in Revenue. In the last year, the revenue decreased by -2.11%.
Measured over the past years, SXTC shows a very negative growth in Revenue. The Revenue has been decreasing by -22.75% on average per year.
EPS 1Y (TTM)44.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.83%
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%30.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SXTC Yearly Revenue VS EstimatesSXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
SXTC Yearly EPS VS EstimatesSXTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTC Price Earnings VS Forward Price EarningsSXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTC Per share dataSXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SXTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINA SXT PHARMACEUTICALS IN

NASDAQ:SXTC (1/17/2025, 8:00:01 PM)

After market: 0.41 0 (-0.1%)

0.4104

+0 (+0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners2.11%
Inst Owner Change136.35%
Ins Owners3.98%
Ins Owner ChangeN/A
Market Cap1.43M
Analysts0
Price TargetN/A
Short Float %13.07%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.74
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.1
EV/EBITDA N/A
EPS(TTM)-13.99
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.55
BVpS4
TBVpS4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.4%
ROE -22.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.73%
FCFM N/A
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
F-Score5
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.47%
Cap/Sales 0.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.6
Quick Ratio 1.51
Altman-Z -1.4
F-Score5
WACC5.2%
ROIC/WACCN/A
Cap/Depr(3y)16.74%
Cap/Depr(5y)40.04%
Cap/Sales(3y)2.08%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%30.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1190.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2310.06%
OCF growth 3YN/A
OCF growth 5YN/A